Top Generic Companies - Market Analysis and Forecasts

Questions: Discounts, Updates etc.

Pages: 320

Price (Single): £1499

Price (Departmental): £2999

Price (Company): £4999

Publication Date: 2008-02-01

Order Online Now

Name:
Email:
Company Name:
Telephone:
Licence Type:
Payment Method:

People that purchased this report also purchased:

Contact LeadDiscovery

If you have questions about this report
To find out if you qualify for a discount
Want a more up to date version
Can't find a report that meets your needs

Search all reports

The generic industry is a fast evolving market with significant lucrative opportunities and high growth potential. This is partly driven by cost-containment in several national healthcare sectors and partly by the need for governments to promote the use of generic products over high-priced originator products without compromising quality.

In 2006, the global generics market attained strong revenues of approximately $65bn, up by 12% in comparison with $58bn in 2005. However and even more remarkable, during the same period, the top 10 leading generic suppliers generated total revenues of $27.9bn, up by a growth rate of 34%. The top 5 companies within that sector experienced significant revenues, with market growth largely driven by significant commercial activities, key Mergers and Acquisition (M&A) and launch of new product in the leading markets.

In light, of the significant number of proprietary branded pharmaceuticals approaching patent expiration in the near-term, it is predicted that the generic market is set to experience further market expansion. It is also predicted that by 2023, the top 10 generic suppliers will experience CAGR of 7%. That significant CAGR, will be driven by generic versions of leading blockbuster drugs presently estimated at $100bn, nearing patent expiration during 2008-2012.

Prominently, amongst the products with looming patent expirations are drugs such as:

Pfizer's Lipitor
AstraZeneca's Nexium
Bristol Myers Squib's Plavix
Pfizer's Norvasc
Lilly's Zyprexa
Janssen's Risperdal
Wyeth's Effexor

In 2007, a total of 14 drugs came off patent in the US market. In 2008, a total of 14 drugs are expected to lose patent protection in the US market. In 2009, five drugs are predicted to becoming off-patent in the US market. In 2010, the world's highest selling drug, Pfizer's Liptor will come off-patent in the US. In the EU market, UCB's Keppra and four other medicines are also expected to lose patent protection. In 2011, 10 major drugs in the US market will also become exposed to generic competition. An estimated 11 drugs will experience generic competition in the EU market during the same year. Significant among these drugs will be Lipitor and Zyprexa.

Moreover, the generic market is projected to further expand through the growing uptake of biogeneric/ biosimilar products. In 2006, biological drugs, the products of biotechnology generated total revenues of $40bn. The US market accounted for a significant proportion of total worldwide sales. Presently, in the EU, the growing popularity of these products is gaining newer heights, with managed care organisations (MCOs), healthcare providers and payers amongst others increasingly requesting these medicines as a significant cost-saving strategy. However, by 2010, an estimated 24 biologic drugs will near patent expiration opening up the market for generic possibilities.

This report provides a company-by-company forecast with a focus on key regions:

Asia

Teva (Asia/ Israel)

Europe

Actavis (Finland)
Merck KGaA (Germany)
Ratiopharm (Germany)
Sandoz (Switzerland)
Stada (Germany)

North America

Apotex (Canada)
Barr (US)
Mylan (US)
Watson (US)

This report includes detailed five-year forecasts over the period 2007-2012, and features 10 and 15-year forecasts to help you understand the medium-term prospects for these markets.

Why You Must Buy This Report:

This report features in-depth primary research, tables, graphs and charts, news, insights, the past and present developments in the market. This report allows you to completely understand the operations of the top 10 generics companies and how this has driven their corporate growth in recent times. In addition, the report places significant emphasis on key strategies that will drive year-on-year sales growth of their leading products. Despite the lucrative opportunities presented to the leading companies through patent expirations, leading generic companies will have to overcome significant hurdles and these are analyzed in this report.

This report is a single tool to equip you with the latest trends in all regional markets and why all (stakeholders) are opting for cheaper generic medicine. The report will also inform you of the major legal challenges that leading companies face to date. The report also analyzes how generic companies are positioning themselves in the face of rising inherent cost of R&D expenditure especially with respect to difficult-to-manufacture biogeneric/ biosimilars. Finally the report presents a 360 degrees overview of requirements set by major regulatory authorities for larger evidence of clinical data before any authorisation.

When you buy this report, you will also get an understanding of how generic suppliers are tackling changes in governmental pharmaceutical policies with respect to cost-cutting as well as other major hurdles

What questions does the report answer?

Who are the generic market leaders?
Which regions dominate the generic market?
Which of the Top Ten companies conducted key M&As to bolster product pipeline?
Have the M&As been successful in expanding product range?
Is the cost of branded medicines justifiable by Big Pharma?
How will the Top Ten account for future revenues?
Will the Top Ten continue to experience market share expansion?
How will the Top Ten overcome the legal battles?
Are the legal battles really worth the cost of the generic medicines?
What direction is Biogenerics marketing taking?
Will the EU regulatory bodies narrow the generic gap between the US?
Will the Top Ten themselves be acquired under mounting pressure of strong market competitions?
Will the rising cost of R&D, deter the Top Ten from investing?
Are the voices of managed care organisations (MCOs), healthcare providers and payers driving down sales of Big Pharm’s blockbusters?
Is the EU a “nice-to-operate-in” or a “must-operate-in” market for the Top Ten?

1. Executive Summary
2. An Overview of The Leading Generics Producers in 2007: 2.1 Generics Medicines Experience Significant Growth in 2006; 2.2 Teva Records Largest Sales of Generic Pharmaceuticals Globally in 2006
3 The World Generics Market: 3.1 The World Generics Market to Grow by over 12% Per Annum to 2010; 3.2 Top 20 Companies To Lose Leading Products To Generic Competition; 3.3 Price is the Principal Competing Factor in the Generics Market; 3.4 Countries with Lowest Branded Drug Prices have the Highest Generic Growth; 3.5 Patent Expiration is the Major Driver in All Generic Markets; 3.6 The US Has The Largest Generics Market; 3.7 The UK has the Highest Generic Penetration by Value in All European Markets; 3.8 Japan An Isolated Case in the Generic Market
4. The US and European Regulation of Generic Drugs: 4.1 Generic Pharmaceuticals in the US Market; 4.3 The Hatch-Waxman Act Title II has Promoted Innovation in the Branded Pharmaceutical Industry; 4.4 The Hatch-Waxman Act Drives Influx Of Generic Pharmacuticals Significantly; 4.5 Marked Difference In European Generics Patents Laws In Comparison With The US; 4.6 European Generic Drug Development: Variation Between European Countries; 4.7 EU Benefits From Long Data Exclusivity Protecting Patents; 4.8 Additional EU Patent Protection is Afforded by Supplementary Protection Certificates; 4.9 Compulsory Licensing Allows Generic Manufacture Before Patent Expiry; 4.10 The WHO and Compulsory Licenses; 4.11 Compulsory Licenses and the TRIPs Agreement; 4.12 The Benefit of Being the First Generic to Market; 4.12 The Advatages of First-to-Market Generics; 4.13 Biogenerics A Continuously Expanding Market; 4.14 Bioequivalence A Growing Concern For The Biogenerics Industry; 4.15 US Biogenerics Regulatory Framework Awaits The Implementation of New Bills; 4.16 European Drug Regulation Framework; 4.17 European Medicines Agency (EMEA) Amends Its Biogeneric Regulation
5 TEVA Pharmaceutical Industries: 5.1 Teva is Listed on Various Stock Exchanges, Including NASDAQ; 5.2 Teva Achieved Sales of $8.4bn in 2006; 5.3 Human Pharmaceuticals Division; 5.4 Active Pharmaceutical Ingredients (API) Division; 5.5 Teva USA; 5.6 Veterinary Products; 5.7 Key Acquisitions by Teva; 5.8 A Brief History of Teva; 5.9 Teva Benefited from an Ambitious Strategy of Acquisition; 5.10 Teva Had Over 150 Products Awaiting FDA Approval at the End of 2006; 5.11 Promising First Quarter Results for 2007; 5.12 Copaxone - Teva's First Innovative Drug to Receive FDA Approval; 5.12 Copaxone - Teva's First Innovative Drug to Receive FDA Approval; 5.13 Azilect - Teva's Recently Launched Innovative Product; 5.14 Teva Has a Diverse Generics Portfolio; 5.15 The Integration of Ivax's Operations Greatly Increased Teva's Strengths in Respiratory Drugs; 15.16 Teva Pharmaceutical Market Forecast 2008-2013 & 2023; 5.17 Pipeline Developments in Teva; 5.18 Teva Has a Very Strong Generics Pipeline in Addition to Innovative Developments; 5.19 Antineoplastics/Immunomodulating Agents; 5.20 Central Nervous System Agents; 5.21 Genitourinary System/Sex Hormones; 5.22 Respiratory System Agents; 5.23 Licensing Deal With Vaccinex for Monoclonal Antibody; 5.24 Teva Collaborates on Protalix's Recombinant Plant Cell Expression Technology; 5.25 Teva And Procognia (Israel) Ltd. Sign an Exclusive Collaboration Agreement for the Development of Biopharmaceuticals
6 Novartis' Sandoz: 6.1 Sandoz is a Leading Supplier of Generics Internationally; 6.2 Novartis' Sandoz Generics Division; 6.3 Sandoz Has A Complex History From Establishment in 1886 to Present; 6.4 Sandoz Has a Broad Product Range, Much of it Due to Acquisition of Generics Companies; 6.5 Retail Generics Produces Finished Dosage Generic Forms; 6.6 Sandoz Products: Retail Generics; 6.7 Sandoz Products: Contract Biopharmaceuticals; 6.8 Sandoz Products: Active Pharmaceutical Ingredients (API); 6.9 Sandoz Products: Product Intermediates; 6.10 Sandoz Achieved Impressive Growth in 2006; 6.11 Sandoz Will Achieve Strong Growth from 2008-2023; 6.12 Sandoz Has Consolidated Its Market Position Through Acquisitions; 6.13 Sandoz Receives Landmark US and European Regulatory Approval for Omnitrope in 2006; 6.14 Sandoz Invests in Low Cost Production; 6.15 The Outlook 2008-2023- Being Part of Novartis Will Confer a Significant Competitive Advantage upon Sandoz
7. Merck KGaA: 7.1 Merck KGaA is a Leading International Producer of Generic Pharmaceuticals; 7.2 Merck Generics Worldwide: the Merck KGaA group of companies; 7.3 Merck Generics Financials, 2006; 7.4 Merck KGaA Generics Segment Forecast, 2008-2013 & 2023; 7.5 Merck Set to See Sustainable Generic Revenues Through Innovation of Product Life Cycle.; 7.6 Major Developments in Merck Generics; 7.7 Merck's Strategic Acquisition of Serono Will Drive Revenues in the Long-Term
8. Ratiopharm: 8.1 Ratiopharm Is a Pioneer In Generics Pharmaceuticals; 8.2 RatioPharm Generics Segment; 8.3 International Sales Drives RatioPharm's Revenue; 8.4 Ratiopharm Leading Generics Sale; 8.5 Ratiopharm Generic Segment Forecast 2008-2013 & 2023; 8.6 Research And Development; 8.7 Litigation and Agreements; 8.8 Mergers and Acquisition
9 Watson Pharmaceuticals: 9.1 History and Background to Watson Pharmaceuticals; 9.2 Watson's Generics Operations - A Large Product Portfolio Combined with A Strong Pipeline; 9.3 Watson's Strategy - The Development of Technologically Challenging and High Demand Products; 9.4 Watson Business Strategy; 9.5 Watson R&D Expenditure Expands; 9.6 Watson's Generic Product Range Accounts for Over Two Thirds of Net Sales; 9.7 Watson's Branded Products Profit Margins decline in 2006; 9.8 Merger Between Watson and Andrx Drives Sales of Generic Products; 9.9 Watson Generics Segment Forecast, 2008-2013 & 2023; 9.10 Watson New Generic Product Launches; 9.11 Watson Puerto Rico Site to Close as Cost Saving Strategy; 9.12 Watson Agreements; 9.13 Watson Alliances and Collaborations; 9.14 Watson’s Branded Pharmaceutical Will Contribute Significantly To Year-on-Year Sales Growth
10 Actavis: 10.1 Actavis Leading European Generic Company; 10.2 Actavis Products Portfolio And Strategic Business Markets; 10.3 Actavis Market Segmentation Market Segmentation; 10.4 Actavis Third-Party Markets; 10.5 Actavis Generics Segment Forecast, 2008-2013 & 2023; 10.6 Actavis’ Pipeline - Strong Product Development and Investment in Manufacturing; 10.7 Mergers, Acquisitions and Agreements; 10.8 Actavis Is Strongly Positioned To Maintain Status As a Leading Generics Supplier
11. Barr Pharmaceuticals Inc: 11.1 Barr Has Developed A Strong Range of Therapeutic Core Competencies; 11.2 Barr's Strengthens Portfolio Through Acquisition of Pliva; 11.3 Barr Experiences Revenue Decline After Transition Period (July1-December 31); 11.4 Barr Products: Specialisation in Oral Contraception and HIV/AIDS; 11.5 Barr Leading Products; 11.6 Barr Key Financials; 11.7. Other Significant Barr Generic Launches; 11.8 Pending Generic Patent Challenges; 11.9 Barr Generics Segment Forecast, 2008-2013 & 2023; 11.10. Proprietary Product Sales; 11.11 Barr Invests Significantly in R&D of Generic And Proprietary Products; 11.12 Barr's Alliances; 11.13 Litigations Facing Barr
12 Stada Healthcare: 12.1 Stada A Leading European Generics Pharmaceutical Company; 12.2 Stada Key Competencies; 12.3 Stada Regional Sales; 12.4 Stada US Markets Revenue Declines; 12.5 Stada Generics Division; 12.6 Stada Branded Products; 12.7 Stada Generics Segment Forecast, 2008-2013 & 2023; 12.8 Stada Product Developments; 12.9 Mergers, Acquisitions and Disposals; 12.10 Stada Initiates Biosimilar Projects
13. Mylan Laboratories: 13.1 Mylan Was Originally a Packaging Company; 13.2 Mylan Leading Therapeutic Classes; 13.3 Mylan Records Highest Sale in US Market; 13.4 Mylan's Pharmaceuticals Product Porfolio Expands Significantly; 13.5 Mylan's Recent Financial Results; 13.6 Mylan New Product Lauches To Drive Revenue Growth; 13.7 Mylan Increases R&D Expenditure; 13.8 Mergers, Acquisitions and Agreements; 13.9 Legal Challenges on Products
14. Apotex: 14.1 Apotex Privately Owned Canadian Pharmaceutical Firm; 14.2 Apotex Geneic Division; 14.3 Apotex Experiences Continuous Growth Revenue; 14.4 Apotex Regional Segmentation; 14.5 Apotex Leading Generic Drugs; 14.6 Apotex Generics Segment Forecast, 2008-2013 & 2023; 14.7 Apotex Research and Development; 14.8 Apotex Second Largest Mergers and Acquisitions; 14.9 Apotex Will Compete Strongly With The Top Five Leading Generic Companies
15. Conclusions: 15.1 Generics Market Bubble-Patent Expiration $100bn Branded Products; 15.2 Major Wave of Patent Expirations To Occur; 15.3 Generic Drugs Uptake in The US on the Rise; 15.4 The UK has the Highest Generic Penetration by Value in All European Markets; 15.5 The Expiration of Branded Patents is The Most Important Driver of Growth in The Sector; 15.6 Characteristics of Differing Regulatory Systems Affect the Market for Generics; 15.7 Biogenerics Are Becoming Increasingly Important; 15.8 Teva Leads The Generic Sector; 15.9 Consolidation to be Key Factor in Growth of Generic Industry; 15.10 Strong Positioning in EU Market Will Be An Influential Factor For High Revenue; 15.11 Generics Sector An Expanding Market With Lucrative Opportunities; 15.12 Strategic Focus On Geographical Markets Will Be Key To Levarging Technological Innovations; 15.13 Growing Presence of Automatic Substitution At Pharmacy Will Drive Generic Growth; 15.14 Top Ten Generic Companies Will Experience Strong Revenues During 2008-2023; 15.15 Device-Driven Products Holds Significant Revenue Potential For Generic Investors; 15.16 Product Life-Cycle Management Will Be Crucial To Generic Revenue Growth
List of Tables: Table 1.1 Top 10 Generic Comapnies, Generics Revenue ($bn) Forecast, 2008-2013,2018 & 2023; Table 2.1 Sales of All Companies: Total Group and Generics Sales,2005-2006; Table 2.2 Sales of All Companies: Total Group Sales,2005-2006; Table 2.3 The Leading Generics Companies: Total Generic Sales Only, 2005-2006; Table 3.1 Major Drugs Losing Patent Expiration in Near-Term; Table 3.2 Branded and Generics Price Differentials in Selected Leading European Countries, 2006; Table 3.3 The Top Ten US Generic Drugs by Revenue ($m) and Units; Table.3.4 Prescription Number (m), 2004 Top 10 Generic Drugs, Dispensed by Prescriptions in the US, 2006; Table 3.5 US Top Ten Generic Drugs as a Function of Combined Branded and Generic Drugs by Prescription Number (m) and Revenues ($m),2006; Table 5.1 Top 20 Leading Pharmaceutical Companies,2006; Table 5.2 Teva Net Sales, Net Income, 2006; Table 5.3 Teva Subsidiaries, 2006; Table 5.4 Sales ($m) by Geographical Area, 2004-2006; Table 5.5 Sales ($m) by Business Division, 2004-2006; Table 5.6 Principal Therapeutic Products Manufactured by Teva, 2007; Table 5.7 Teva Pharmaceuticals: Top Five Therapeutic Classes, 2005-2006; Table 5.8 Pharmaceuticals: Leading International Products, 2005-2006; Table 5.9 Teva Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Table 5.10 R&D Investment by Teva, 2002-2006; Table 5.11 Summary of R&D Pipeline; Table 6.1 Sandoz Net Sales ($m) and Other Key Financials, 2006; Table 6.2 Sandoz Net Sales (%) by Region, 2006; Table 6.3 Sandoz Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Table 7.1 Sales of Pharmaceutical and Chemical Division, 2002-2006; Table 7.2 Revenues of Pharmaceutical Businesses, 2002-2006; Table 7.3 Merck KGaA Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Table 8.1 Revenues of Top Ten Selling Therapeutic Classes,2006; Table 8.2 Revenues of Top Ten Selling Generics, 2006; Table 8.3 Regional Sale Distribution, 2006; Table 8.4 Sales Distribution in Major EU Markets, 2006; Table 8.5 Sales Distribution in Canada and the US, 2006; Table 8.6 Sales Distribution in Africa, Asia and Australian Markets, 2006; Table 8.7 Sales Distribution in Latin and South American Markets, 2006; Table 8.8 Ratiopharm Subsidiaries; Table 8.9 Ratiopharm Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Table 9.1 Total Revenue including Major Operations, 2006; Table 9.2 Net Revenue In Comparison With Other Operational Losses, 2006; Table 9.3 Generic Segment Sales, 2006; Table 9.4 Revenues of Branded Products Operations, 2006; Table 9.5 R&D and Other Operating Expenditure, 2006; Table 9.6 Watson Nephrology Product Portfolio; Table 9.7 Watson Urology Product Portfolio; Table 9.8 Pain Product Portfolio; Table 9.9 Women's Health Product Portfolio; Table 9.10 Other Specialty Product Portfolio; Table 9.11 Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Table 10.1 Actavis Total Revenue ($m) and Net Profit ($m), 2006; Table 10.2 Actavis Leading Products in Major Markets, 2006; Table 10.3 Actavis Revenue ($m) in Key Regions, 2006; Table 10.4 Actavis Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Table 11.1 Barr Total Revenues and Net Earnings, 2003-2006; Table 11.2 Comparison of the six months ended December 31 2006 and December 31, 2005; Table 11.3 Barr Leading Products, 2006; Table 13.4 Total Revenue of Oral Contraceptive, 2004-2006; Table 13.5 Barr Patent Challenges and Valuation; Table 11.6 Barr Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Table 11.7 Total Revenue of Proprietary Products, 2004-2006; Table 11.8 Total Revenue of Proprietary Products, 2004-2006; Table 12.1 Total Revenue ($m), Net Income ($m) and Operating Profit ($m), 2003-2006; Table 12.2 Stada Core Business Revenues, 2006; Table 12.3 Regional Sales Distribution, 2003-2006; Table 12.4 Stada US Revenue ($m), 2002-2006; Table 12.5 Regional Sales Distribution, 2003-2006; Table 12.6 Revenues in Leading EU Markets, 2006; Table 12.7 Revenue in Five Leading EU Markets, 2006; Table 12.8 Revenue in Other Leading EU Markets, 2006; Table 12.9 Revenue Top Five Leading Generic Products, 2006; Table 12.10 Stada Top Five Branded Products Division Revenue, 2006; Table 12.11 Stada Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Table 12.12 Stada M&A Operations, 2006; Table 12.13 Stada M&A Operations, 2006; Table 13.1 Total Revenue ($m) and Profit ($m) for Mylan; Table 13.2 Total Revenue ($m) of Mylan Leading Therapeutic Classes; Table 13.3 Mylan's Leading Products, 2006; Table 13.4 Mylan Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Table 13.5 Mylan's R&D Investment, 2003-2007; Table 14.1 Apotex Revenues, 2004-2007; Table 14.2, Market Share of Apotex Leading Therapeutic Classes, 2006; Table 14.3 Apotex Geographical Revenues, 2006; Table 14.4 Apotex Revenues in US and Canada, 2006; Table 14.5 Apotex Revenues in Key EU Markets, 2006; Table 14.6 Apotex Revenues in Key Latin American Markets, 2006; Table 14.7 Apotex Revenues in Key Central American Markets, 2006; Table 14.8 Apotex Revenues in Key Africa, Asia& Australia Markets, 2006; Table 14.9 Apotex Revenues For Leading Drugs, 2006; Table 14.10 Apotex Revenues For Top Five Drugs, 2006; Table 14.11 Apotex Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Table 15.1 Near-term Patent Expiration ,207-2009
List of Figures: Figure 1.1 Top 10 Generic Comapnies, Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Figure 2.1 Sales 2004-2006 All Companies: Total Group Sales; Figure 2.2 Market Share of Sales of All Companies: Total Group Sales,2006; Figure 2.3 The Leading Generics Companies: Total Generic Sales Only, 2005-2006; Figure 2.4 Market Share of Sales of All Companies: Generic Sales Only, 2006; Figure 3.1 Per Capita Growth Rate for National Health Expenditure Vs Prescription Drugs Over Four Decades; Figure 5.1 Teva Net Sales, 2006; Figure 5.2 Teva Net Income, 2006; Figure 5.3 Sales ($m) by Geographical Area, 2004-2006; Figure 5.4 Sales ($m) by Business Division, 2004-2006; Figure 5.5 Teva Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Figure 5.6 R&D Investment by Teva, 2002-2006; Figure 6.1 Sandoz Net Sales ($m) and Other Key Financials, 2006; Figure 6.2 Sandoz Net Sales (%) by Region, 2006; Figure 6.3 Sandoz Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Figure 7.1 Sales of Pharmaceutical and Chemical Division, 2002-2006; Figure 7.2 Revenues of Pharmaceutical Businesses, 2002-2006; Figure 7.3 Market Share of Merck KGaA Businesses, 2006; Figure 7.4 Regional Revenues of Generic Pharmaceuticals, 2006; Figure 7.5 Regional Market Share of Generic Pharmaceuticals, 2006; Figure 7.6 Merck KGaA Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Figure 8.1 Market Share of Ratiopharm Top Ten Selling Therapeutic Classes,2006; Figure 8.2 Market Share of Ratiopharm Top Ten Selling Generics, 2006; Figure 8.3 Regional Sale Distribution, 2006; Figure 8.4 Sales Distribution in Major EU Markets, 2006; Figure 8.5 Sales Distribution in Canada and the US, 2006; Figure 8.6 Sales Distribution in Africa, Asia and Australian Markets, 2006; Figure 8.7 Market Share Distribution in Latin American Markets, 2006; Figure 8.8 Ratiopharm Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Figure 9.1 Total Revenue Including Major Operations, 2006; Figure 9.2 Net Revenue In Comparison With Other Operational Losses, 2006; Figure 9.3 Market Share of Branded Products Vs Generics; Figure 9.4 Watson's R&D Expenditure, 2002-2006; Figure 9.5 Generic Segment Sales, 2006; Figure 9.6 Revenues of Branded Products Operations,2006; Figure 9.7 R&D and Other Operating Expenditure, 2006; Figure 9.8 Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Figure 9.9 Watson ANDA Submission, 2002-2006; Figure 9.10 Watson ANDA Pending Approvals 2002-2006; Figure 10.1 Actavis Total Revenue ($m) and Net Profit ($m), 2006; Figure 10.2 Actavis Regional Market Share Distribution; Figure 10.3 Market Share of Actavis Leading Products in Major Markets, 2006; Figure 10.4 Actavis Revenue ($m) in Key Regions, 2006; Figure 10.5 Actavis Market Share in CEEA Market 2006; Figure 10.6 Actavis Market Share in WEMEA Market, 2006; Figure 10.7 Actavis Third Party Division Market Share Market, 2006; Figure 10.8 Actavis Third Party Division Regional Market Share Market, 2006; Figure 10.9 Actavis Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Figure 11.1 Barr Total Revenues and Net Earnings, 2003-2006; Figure 11.2 Barr Leading Products, 2006; Figure 11.3 Total Revenue of Oral Contraceptive, 2004-2006; Figure 11.4 Barr Generic Products Revenues ($bn) Forecast, 2008-2013, 2018 & 2023; Figure 11.5 Total Revenue of Proprietary Products, 2004-2006; Figure 11.6 Total Revenue of Proprietary Products, 2004-2006; Figure 12.1 Net Income ($m) and Operating Profit ($m), 2003-2006; Figure 12.2 Stada Core Business Revenues, 2006; Figure 12.3 Market Share of Stada Core Business Revenues, 2006; Figure 12.4 Regional Sales Distribution, 2003-2006; Figure 12.5 Market share of Regional Sales Distribution, 2006; Figure 12.6 Stada US Revenue ($m), 2002-2006; Figure 12.7 Stada Market Share in Six Major Regions, 2006; Figure 12.8 Market Share Revenues in Leading EU Markets, 2006; Figure 12.9 Revenue in Five Leading EU Markets, 2006; Figure 12.10 Revenue in Other Leading EU Markets, 2006; Figure 12.11 Stada Generic Division Revenue, 2003-2006; Figure 12.12 Revenue Top Five Generic Products, 2006; Figure 12.13 Stada Branded Products Division Revenue, 2003-2006; Figure 12.14 Market Share of Stada's Top Five Branded Products Division Revenue, 2006; Figure 12.15 Stada Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Figure 12.16 Stada M&A Operations, 2006; Figure 12.17 Stada M&A Disposals Revenue, 2006; Figure 13.1 Mylan Total Revenue ($m) and Profit ($m),2003-2006; Figure 13.2 Total Revenue ($m) of Mylan Leading Therapeutic Classes; Figure 13.3 Market Share Distribution of Mylan's Leading Therapeutic Classes; Figure 13.4 Total Revenue Distribution in Major Geographical markets, 2006; Figure 13.5 Market Share of Mylan's Leading Products, 2006; Figure 13.6 Mylan Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023; Figure 13.7 Mylan's R&D Investment, 2003-2007; Figure 14.1 Apotex Revenues, 2004-2007; Figure 14.2 Market Share of Apotex Leading Therapeutic Classes, 2006; Figure 14.3 Apotex Geographical Revenues, 2006; Figure 14.4 Market Share of Apotex Revenues in US and Canada, 2006; Figure 14.5 Market Share of Apotex Revenues in Key EU Markets, 2006; Figure 14.6 Market Share of Apotex Revenues in Key Latin American Markets, 2006; Figure 14.7 Apotex Revenues in Key Central American Markets, 2006; Figure 14.8 Market Share of Apotex Revenues in Key Africa, Asia & Australia Markets, 2006; Figure 14.9 Apotex Revenues For Leading Drugs, 2006; Figure 14.10 Apotex Revenues For Top Five Drugs, 2006; Figure 14.11 Apotex Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023

Other users found this report page using the following search terms: generic biogeneric biosimilar generic companies top generics market 20 2008 share 10 uk

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.

Top Generic Companies - Market Analysis and Forecasts

Credit Card Details

Invoice Details

Table of Contents